Table 1.
Epidemiology of patients with early breast cancer stage I-III
| Epidemiology | Total (N = 559 632) | SEER-White (N = 496 332) | SEER-Asian (N = 18 279) | ABCCG-Asian (N = 45 021) | |
|---|---|---|---|---|---|
| Age at diagnosis | Patients, n | 559 618 | 496 332 | 18 279 | 45 007 |
| Median (range) | 61 (2-117) | 62 (2-117) | 58 (20-108) | 51 (17-97) | |
| Histologic grade | Patients, n | 547 267 | 496 332 | 18 279 | 32 656 |
| Grade I, n (%) | 123 225 (22.52) | 113 675 (22.90) | 3967 (21.70) | 5583 (17.10) | |
| Grade II, n (%) | 228 224 (41.7) | 206 437 (41.59) | 7606 (41.61) | 14 181 (43.43) | |
| Grade III, n (%) | 159 330 (29.11) | 141 037 (28.42) | 5402 (29.55) | 12 891 (39.48) | |
| Others (unknown), n (%) | 36 488 (6.67) | 35 183 (7.09) | 1304 (7.13) | 1 (0.00) | |
| Histologic subtype | Patients, n | 559 632 | 496 332 | 18 279 | 45 021 |
| Invasive ductal carcinoma, n (%) | 409 981 (73.26) | 357 590 (72.05) | 14 176 (77.55) | 38 215 (84.88) | |
| Invasive lobular carcinoma, n (%) | 49 912 (8.92) | 47 089 (9.49) | 983 (5.38) | 1840 (4.09) | |
| Others, n (%) | 99 739 (17.82) | 91 653 (18.47) | 3120 (17.07) | 4966 (11.03) | |
| Stage | Patients, n | 420 634 | 365 765 | 13 567 | 41 302 |
| I, n (%) | 172 390 (40.98) | 149 972 (41) | 5713 (42.11) | 16 705 (40.45) | |
| II, n (%) | 184 128 (43.77) | 160 757 (43.95) | 6151 (45.34) | 17 220 (41.69) | |
| III, n (%) | 64 116 (15.24) | 55 036 (15.05) | 1703 (12.55) | 7377 (17.86) | |
| T | Patients, n | 536 730 | 477 178 | 17 637 | 41 915 |
| 0, n (%) | 1414 (0.26) | 807 (0.17) | 28 (0.16) | 579 (1.38) | |
| 1, n (%) | 339 556 (63.26) | 304 167 (63.74) | 11 170 (63.33) | 24 219 (57.78) | |
| 2, n (%) | 154 106 (28.71) | 134 238 (28.13) | 5237 (29.69) | 14 631 (34.91) | |
| 3, n (%) | 26 963 (5.02) | 24 275 (5.09) | 815 (4.62) | 1873 (4.47) | |
| 4, n (%) | 14 691 (2.74) | 13 691 (2.87) | 387 (2.19) | 613 (1.46) | |
| N | Patients, n | 544 934 | 483 538 | 17 831 | 43 565 |
| 0, n (%) | 382 240 (70.14) | 343 010 (70.94) | 13 007 (72.95) | 26 223 (60.19) | |
| 1, n (%) | 118 346 (21.72) | 102 684 (21.24) | 3608 (20.23) | 12 054 (27.67) | |
| 2, n (%) | 28 586 (5.25) | 24 466 (5.06) | 811 (4.55) | 3309 (7.60) | |
| 3, n (%) | 15 762 (2.89) | 13 378 (2.77) | 405 (2.27) | 1979 (4.54) | |
| Breast subtype | Patients, n | 305 881 | 258 102 | 9902 | 37 877 |
| HR+/HER2−, n (%) | 228 049 (74.55) | 195 877 (75.89) | 7266 (73.38) | 24 906 (65.75) | |
| HR+/HER2+, n (%) | 31 110 (10.17) | 25 661 (9.94) | 1078 (10.89) | 4371 (11.54) | |
| HR–/HER2+, n (%) | 14 339 (4.69) | 10 218 (3.96) | 568 (5.74) | 3553 (9.38) | |
| Triple-negative, n (%) | 32 383 (10.59) | 26 346 (10.21) | 990 (10) | 5047 (13.32) | |
ABCCG, Asian Breast Cancer Cooperative Group; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; SEER, Surveillance, Epidemiology, and End Results Program.